Simple Once Daily Triple Regimen Including Tenofovir, Emtricitabine and Efavirenz in HIV-1 Infected Patients (ANRS 1207)

Inclusion Criteria: * Documented infection with HIV-1 (ELISA- Western Blot) * Outpatient of masculine or feminine gender * In female patients any risk of pregnancy must be avoid: women at least 1 year past menopause or being confirmed sterile or having an effective contraceptive device * No previous treatment with antiretroviral therapy * CDC group C (except tuberculosis if CD4 count is over 350 /ml), CDC group B with CD4+ count under 350/ml and CDC group A with CD4 count under 200/ml. * Patient has provided informed written consent * Patient must agree not to take any concomitant medication throughout the duration of the study without first informing the investigator Exclusion Criteria: * Deficiency of the patient rendering participation in the study or understanding of the information imparted difficult or even impossible * Patient participating in a different clinical study * Presence of serious or developing pathology * Severe liver failure (TP under 50% et bilirubinemia over 3 LSN) * Thrombocytopenia with platelet level under 50 000 cells /ml * Known severe renal pathology (creatinine clearance under 50 ml/min) * Clinical or biological problem corresponding to indications of grade over or equal 3 of WHO classification * Karnofsky under 70 percent * Opportunistic infections * Patients taking medications not recommended in the context of the protocol